Since Prima‐1Met has been shown to target TrxR1,41 the authors investigated whether AF could display the same anticancer activity on a panel of 18 myeloma cell lines and in 10 primary cells from patients with multiple myeloma or plasma cell leukemia. Here, TXNRD1 is linked to plasma cell myeloma.